Visiox Pharma, LLC Asset Profile

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

Year established

2019

Location

NY US

Primary Industry

Biotechnology

About

Based in New York, US, and founded in 2021, Visiox Pharma, LLC, a.k.a. Visiox Pharma operates as a manufacturer of medicinal drugs called PDP-716 and SDN-037 that are used for treating eye diseases. In August 2022, Visiox Pharma, LLC, raised USD 1.30 million in seed funding led by Founding Partners. As of August 2023, Ryan Bleeks is the CEO of the company. The flagship product, Omlonti® (omidenepag isopropyl ophthalmic solution) 0.002%, stands as an EP2 receptor agonist designed to combat ocular hypertension and open-angle glaucoma. PDP-716, an innovative once-daily brimonidine for ocular hypertension and open-angle glaucoma, follows the product suit. Additionally, SDN-037, a twice-daily topical difluprednate catering to post-surgical inflammation and pain. Visiox's strategic portfolio expansion includes TearActTM delivery technology, along with its acquisition of PDP-716 and SDN-037 from Sun Pharma Advanced Research Company Ltd.

Primary Industry

Biotechnology

Sub Industries

Biopharmaceuticals, Optometrists & Opticians Products and Services

Website

www.visioxpharma.com

Verticals

Manufacturing

Company Stage

Angel & Seed

Total Amount Raised

Subscriber access only

Employee Data

Want to see the Employee Count?

Request a demo for full access to this profile.

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.